---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References"
description: "Reference list for the formulary evidence report on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib. 206 cited documents."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References

<a id="references"></a>

## 5 References

1. [Alban et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12784650/)
2. [Alfaar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40936061/)
3. [Algazi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767160/)
4. [American Cancer Society eye cancer survival rates (2025)](https://www.cancer.org/cancer/types/eye-cancer/detection-diagnosis-staging/survival-rates.html)
5. [American Cancer Society key statistics for eye cancer (2026)](https://www.cancer.org/cancer/types/eye-cancer/about/key-statistics.html)
6. [Atkinson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5303646/)
7. [Bakalian et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18281525/)
8. [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)
9. [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10288853/)
10. [Bedikian et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12777987/)
11. [BioSpace (2026)](https://www.biospace.com/drug-development/ideaya-and-serviers-eye-cancer-drug-heads-to-fda-after-delivering-best-in-class-efficacy)
12. [Bristol-Myers Squibb OPDIVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125554s138lbl.pdf)
13. [Bristol-Myers Squibb OPDUALAG prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761234s011lbl.pdf)
14. [Bristol-Myers Squibb YERVOY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125377s140lbl.pdf)
15. [Brown et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8964647/)
16. [Brown et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36848060/)
17. [Buder et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3892799/)
18. [CADTH pharmacoeconomic review, tebentafusp (2023)](https://www.ncbi.nlm.nih.gov/books/NBK596610/)
19. [CADTH rapid response report, radioembolization for uveal melanoma liver metastases (2018)](https://www.ncbi.nlm.nih.gov/books/NBK537723/)
20. [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1)
21. [Campbell et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41807618/)
22. [Carvajal et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4249701/)
23. [Carvajal et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29528792/)
24. [Carvajal et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9671803/)
25. [Carvajal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36600005/)
26. [Castle Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1447362/000162828026012272/cstl-20251231.htm)
27. [Chen et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4524511/)
28. [Cheng et al. (2017)](https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-20th-annual-european-congress/quantifying-standard-of-care-soc-hospital-related-resource-utilisation-for-metastatic-uveal-melanoma-mum-patients-in-nhs-england-nhse-using-the-hospital-episodes-statistics-hes-dataset)
29. [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)
30. [ClinicalTrials.gov NCT03070392 API record](https://clinicaltrials.gov/api/v2/studies/NCT03070392)
31. [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)
32. [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)
33. [ClinicalTrials.gov NCT05987332 version 1](https://clinicaltrials.gov/study/NCT05987332?tab=history&a=1)
34. [ClinicalTrials.gov NCT05987332 version 39](https://clinicaltrials.gov/study/NCT05987332?tab=history&a=39)
35. [ClinicalTrials.gov NCT06581406](https://clinicaltrials.gov/study/NCT06581406)
36. [CMS Local Coverage Determination L37130, MolDX: DecisionDx-UM (2025)](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37130)
37. [CMS Quality ID 509 measure specification (2025)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_509_MIPSCQM.pdf)
38. [Collaborative Ocular Melanoma Study Group (2001)](https://pubmed.ncbi.nlm.nih.gov/11346394/)
39. [Damato et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22503229/)
40. [de Melo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11299924/)
41. [Delcath HEPZATO KIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf)
42. [Delcath Systems Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/872912/000162828026012019/dcth-20251231.htm)
43. [Diener-West et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15197206/)
44. [Diener-West et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16344433/)
45. [Dimitriou et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39647344/)
46. [Eleuteri et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33516960/)
47. [Ellis et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10689125/)
48. [EMA orphan designation EU/3/25/3122 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3122)
49. [Eskelin et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10091801/)
50. [Eskelin et al. (2002)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1771030/)
51. [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)
52. [European Medicines Agency KIMMTRAK orphan maintenance assessment report (2022)](https://www.ema.europa.eu/documents/orphan-maintenance-report/kimmtrak-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)
53. [FDA draft guidance on accelerated approval of oncology therapeutics (2023)](https://www.fda.gov/media/166431/download)
54. [FDA guidance page, accelerated approval of oncology therapeutics (2023)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics)
55. [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)
56. [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=873322)
57. [FDA SeCore CDx HLA Sequencing System De Novo decision summary (2022)](https://www.fda.gov/media/163612/download)
58. [FDA UNII record E0YF0M8O09](https://precision.fda.gov/uniisearch/srs/unii/E0YF0M8O09)
59. [G-BA resolution, tebentafusp reassessment D-995 (2024)](https://www.g-ba.de/downloads/91-1455-1022/2024-06-25_Current-Version_Tebentafusp_D-995_EN.pdf)
60. [García-Mulero et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732647/)
61. [Gardner et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25211165/)
62. [Garg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8961763/)
63. [Gonsalves et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6776232/)
64. [Harbour et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3087380/)
65. [HAS Transparency Committee opinion, KIMMTRAK (2023)](https://www.has-sante.fr/jcms/p_3412130/en/kimmtrak-tebentafusp-uveal-melanoma)
66. [Hassel et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/37595494/)
67. [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)
68. [Haystack Project press release, uveal melanoma Patient Oriented Value report (2022)](https://haystackproject.org/s/Press-Release-UV-POV-vf.pdf)
69. [Heppt et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28648699/)
70. [Heppt et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6854774/)
71. [Hikma Dacarbazine for Injection prescribing information (2020)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d81315c-7021-4091-b703-ad135390c936)
72. [Honoré et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13641210/)
73. [Hu et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16226513/)
74. [Hughes et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185532/)
75. [IDEAYA Biosciences clinical trials and expanded access policy](https://www.ideayabio.com/clinical-trials)
76. [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)
77. [IDEAYA Biosciences Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025022183/idya-20241231.htm)
78. [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)
79. [IDEAYA Biosciences Form 10-Q, first quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526206357/idya-20260331.htm)
80. [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)
81. [IDEAYA Biosciences Form 8-K, Servier license agreement (2025)](https://www.sec.gov/Archives/edgar/data/1676725/000119312525193238/d800731d8k.htm)
82. [IDEAYA Biosciences press release, 2026 corporate objectives (2026)](https://media.ideayabio.com/2026-01-11-IDEAYA-Biosciences-Provides-a-Business-Update-and-Outlines-2026-Corporate-Objectives-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference)
83. [IDEAYA Biosciences press release, End-of-Phase 1 meeting with FDA (2019)](https://media.ideayabio.com/2019-10-31-IDEAYA-Biosciences-Reports-End-of-Phase-1-Meeting-with-FDA-for-IDE196-Confirms-Acceptability-of-Single-Arm-Trial-Design-for-Potential-Phase-2-Registration-Enabling-Study-in-Metastatic-Uveal-Melanoma)
84. [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)
85. [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)
86. [IDEAYA Biosciences press release, Fast Track designation (2022)](https://media.ideayabio.com/2022-12-05-IDEAYA-Biosciences-Receives-Fast-Track-Designation-for-Darovasertib-Combination-Therapy-with-Crizotinib-for-the-Treatment-of-Metastatic-Uveal-Melanoma)
87. [IDEAYA Biosciences press release, FDA Type C meeting and interim phase 2 data (2023)](https://media.ideayabio.com/2023-04-23-IDEAYA-Announces-Positive-Interim-Phase-2-Data-for-Darovasertib-and-Crizotinib-Combination-and-Successful-FDA-Type-C-Meeting-on-Registrational-Trial-Design-for-Accelerated-Approval-in-First-Line-Metastatic-Uveal-Melanoma)
88. [IDEAYA Biosciences press release, first quarter 2026 results (2026)](https://media.ideayabio.com/2026-05-05-IDEAYA-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update)
89. [IDEAYA Biosciences press release, first-line OptimUM-01 overall survival at SMR 2025 (2025)](https://media.ideayabio.com/2025-10-20-IDEAYA-Biosciences-Reports-Positive-Median-Overall-Survival-Data-from-Phase-2-Trial-of-the-Darovasertib-and-Crizotinib-Combination-in-First-line-Metastatic-Uveal-Melanoma-at-the-2025-Society-for-Melanoma-Research-Congress)
90. [IDEAYA Biosciences press release, fourth quarter and full year 2025 results (2026)](https://media.ideayabio.com/2026-02-17-IDEAYA-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update)
91. [IDEAYA Biosciences press release, IDMC move-forward dose recommendation (2024)](https://media.ideayabio.com/2024-12-17-IDEAYA-Announces-IDMC-Recommendation-of-Move-Forward-Dose-in-Part-2a-of-Registration-Enabling-Trial-of-Darovasertib-and-Crizotinib-Combination-in-1L-HLA-A2-Negative-Metastatic-Uveal-Melanoma)
92. [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)
93. [IDEAYA Biosciences press release, OptimUM-02 full enrollment (2025)](https://media.ideayabio.com/2025-12-11-IDEAYA-Biosciences-Completes-Targeted-Full-Enrollment-in-Randomized-Pivotal-Phase-2-3-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A2-Negative-Metastatic-Uveal-Melanoma)
94. [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)
95. [IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026)](https://media.ideayabio.com/2026-09-09-IDEAYA-Biosciences-and-Servier-Announce-First-Patient-Dosed-in-OptimUM-11-Global-Phase-3-Registrational-Trial-of-Darovasertib-and-Crizotinib-as-Adjuvant-Therapy-for-Subjects-with-Uveal-Melanoma)
96. [IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021)](https://media.ideayabio.com/2021-12-07-IDEAYA-Reports-Clinical-Data-from-Phase-2-Expansion-Dose-of-Darovasertib-and-Crizotinib-Synthetic-Lethal-Combination-in-Heavily-Pre-Treated-Metastatic-Uveal-Melanoma)
97. [IDEAYA Biosciences press release, Real-Time Oncology Review (2026)](https://media.ideayabio.com/2026-04-30-IDEAYA-Biosciences-to-Initiate-New-Drug-Application-Submission-from-the-Darovasertib-OptimUM-02-Trial-under-the-Oncology-Center-of-Excellence-Real-time-Oncology-Review-RTOR-Program)
98. [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)
99. [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update)
100. [IDEAYA Biosciences press release, updated OptimUM-02 topline guidance (2026)](https://media.ideayabio.com/2026-03-22-IDEAYA-Biosciences-Upcoming-Investor-Relations-Events-and-Updated-Darovasertib-Topline-Results-Guidance-from-Phase-2-3-OptimUM-02-Trial)
101. [Immunocore Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/imcr-20251231.htm)
102. [Immunocore KIMMTRAK prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf)
103. [Immunocore KIMMTRAK price change notice (2026)](https://www.immunocore.com/download_file/force/321/0)
104. [Jager et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32273508/)
105. [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)
106. [Johansson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4826231/)
107. [Johnson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8063157/)
108. [Joseph et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13568816/)
109. [Kentucky Department for Medicaid Services clinical diagnostic laboratory fee schedule (2026)](https://www.chfs.ky.gov/agencies/dms/DMSFeeRateSchedules/2026ClinicalLabRates.pdf)
110. [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)
111. [Kim et al. (2010)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/425938)
112. [Koumprentziotis et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13664555/)
113. [Kujala et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14578381/)
114. [Labcorp test 167107, HLA A A*02:01-Specific](https://www.labcorp.com/tests/167107/hla-a-a-02-01-specific)
115. [Lane et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6142974/)
116. [Lanzafame et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12984979/)
117. [Leyvraz et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4433517/)
118. [Liu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42152179/)
119. [Luckett et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12105258/)
120. [Luke et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7055933/)
121. [Luo et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37650713/)
122. [Mahendraraj et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5221652/)
123. [Maio et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24067719/)
124. [Mariani et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19329272/)
125. [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)
126. [McKean et al. (2025)](https://www.ideayabio.com/sites/default/files/publications/2026-11/SMR-2025-McKean-OptimUM-01.pdf)
127. [McKean et al. (2026a)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-McKean-OptimUM-01.pdf)
128. [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)
129. [MedlinePlus crizotinib drug information (2022)](https://medlineplus.gov/druginfo/meds/a612018.html)
130. [Melia et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11158813/)
131. [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/)
132. [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s195lbl.pdf)
133. [Moore et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5032652/)
134. [Najjar et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7319717/)
135. [Nathan et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34551229/)
136. [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)
137. [National Comprehensive Cancer Network Uveal Melanoma guideline](https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf)
138. [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/darovasertib)
139. [Ng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045555/)
140. [NHS England evidence summary, chemosaturation for liver metastases from ocular melanoma (2015)](https://www.engage.england.nhs.uk/consultation/clinical-commissioning-wave6/user_uploads/a02-x05-chemosaturation-evidnc-rev.pdf)
141. [NICE resource impact summary report, tebentafusp (2025)](https://www.nice.org.uk/guidance/ta1027/resources/resource-impact-summary-report-13620251053/chapter/Resource-impact-summary-report)
142. [NICE technology appraisal guidance TA1027, committee discussion (2025)](https://www.nice.org.uk/guidance/TA1027/chapter/committee-discussion)
143. [NICE technology appraisal guidance TA1027, information about tebentafusp (2025)](https://www.nice.org.uk/guidance/ta1027/chapter/2-Information-about-tebentafusp)
144. [NICE technology appraisal guidance TA1027, recommendations (2025)](https://www.nice.org.uk/guidance/ta1027/chapter/1-Recommendations)
145. [Ocumel Canada survey report, the ocular melanoma landscape in Canada (2021)](https://saveyourskin.ca/_files/ugd/e08cdc_41dfa819c12143e2a766b820f9cdeeab.pdf)
146. [Olofsson Bagge et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10414734/)
147. [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)
148. [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)
149. [Onken et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3404209/)
150. [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)
151. [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)
152. [Ott et al. (2026a)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-3-4/clinical-and-economic-burden-of-metastatic-uveal-melanoma-a-retrospective-analysis-of-commercially-insured-medicare-and-medicaid-patients-in-the-united-states)
153. [Ott et al. (2026b)](https://www.ispor.org/docs/default-source/cti-meeting-21555-documents/38342afa-bde4-4633-bef6-da8a6d3fd1ee.pdf?sfvrsn=608231d6_0)
154. [Pelster et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257877/)
155. [Pfizer XALKORI Connecticut price disclosure (2026)](https://cdn.pfizer.com/pfizercom/products/ctprescribers/XALKORICTPriceDisclosureShortForm03122026.pdf)
156. [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)
157. [Pham et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37199712/)
158. [Piperno-Neumann et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4786360/)
159. [Piperno-Neumann et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32029634/)
160. [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)
161. [Piperno-Neumann et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12962742/)
162. [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)
163. [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)
164. [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)
165. [Piulats et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33417511/)
166. [Piulats et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38048850/)
167. [Radivoyevitch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8130945/)
168. [Rantala et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6887637/)
169. [Rantala et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8081447/)
170. [Rantala et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34999237/)
171. [Resnick (2026)](https://www.ajmc.com/view/considerations-for-use-of-tebentafusp-a-bite-approved-for-rare-high-risk-uveal-melanoma)
172. [Ribeiro et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903102-2/fulltext)
173. [Robertson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5619925/)
174. [Rodrigues et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5951831/)
175. [Rodrigues et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40628555/)
176. [Rola et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9102800/)
177. [Rossi et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6584707/)
178. [Roth et al. (2024)](https://cosa-2024.p.asnevents.com.au/days/2024-11-14/abstract/108393)
179. [Rowcroft et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31791894/)
180. [Sacco et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38547774/)
181. [Sacco et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11163599/)
182. [Salama et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-1-5/contemporary-real-world-patient-characteristics-treatment-patterns-and-clinical-outcomes-in-metastatic-uveal-melanoma-in-the-united-states)
183. [Sato et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12666308/)
184. [Schinzari et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29076951/)
185. [Schuermeyer et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26539659/)
186. [Scottish Medicines Consortium advice SMC2910, tebentafusp (2026)](https://scottishmedicines.org.uk/media/10462/tebentafusp-kimmtrak-resubmission-final-june-2026-for-website.pdf)
187. [Shoushtari et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8583628/)
188. [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)
189. [Steckler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8901542/)
190. [Steeb et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30205280/)
191. [Tong et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11164794/)
192. [Valsecchi et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4417549/)
193. [van den Hoek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41785896/)
194. [van der Kooij et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40680464/)
195. [Van Raamsdonk et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3107972/)
196. [Vigneswaran et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/)
197. [Visser et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38198520/)
198. [Wagle et al. (2021)](https://aacrjournals.org/cancerres/article/81/13_Supplement/1343/667196/Abstract-1343-Preclinical-evaluation-of-a-PKC-and)
199. [Wei et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9540230/)
200. [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)
201. [WHO Collaborating Centre ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L01ED01)
202. [Xu et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6751472/)
203. [Yamada et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10991441/)
204. [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/)
205. [Zager et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12130151/)
206. [Zimmer et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4356548/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
